Remote Electrical Neuromodulation (REN) is a USFDA approved treatment for migraines that leverages electrical stimulation to alleviate pain. Unlike traditional medications, REN avoids side effects and also is devoid of overuse headaches. REN works by targeting peripheral nerves, which in turn activates the body’s natural pain modulation mechanisms, thereby reducing the reliance on medications. Clinical studies have shown REN to be effective for acute treatment as well as prevention of migraine. It has a favorable safety profile and is also cleared for usage from 12 years of age. Patients have reported significant improvements in their quality of life, thanks to the reduction in migraine-related disability.